Four IPOs are scheduled to raise $1.8 billion in the shortened holiday week, featuring a diverse group of foreign issuers. China’s leading e-cigarette brand RLX Technology (RLX) plans to raise $1.0 billion at a $14.0 billion...read more
Seven IPOs and five SPACs entered public markets this past week, led by high-flying Jamf Holding (JAMF) and the largest SPAC ever Pershing Square Tontine Holdings (PSTHU). Four sizable biotechs all priced at the high end of...read more
Annexon, a Phase 1 biotech developing therapies for rare autoimmune diseases, raised $251 million by offering 14.8 million shares at $17, above the narrowed range of $15 to $16. The company offered 2.3 million more shares than anticipated. It originally...read more
Annexon, a Phase 1 biotech developing therapies for rare autoimmune diseases, raised the proposed deal size for its upcoming IPO on Thursday. The South San Francisco, CA-based company now plans to raise $194 million by offering 12.5 million shares at a...read more
US IPO Week Ahead: Foreign issuers dominate a 4 IPO week
Four IPOs are scheduled to raise $1.8 billion in the shortened holiday week, featuring a diverse group of foreign issuers. China’s leading e-cigarette brand RLX Technology (RLX) plans to raise $1.0 billion at a $14.0 billion...read more
US IPO Weekly Recap: Software and SPACs shine in a 7 IPO week
Seven IPOs and five SPACs entered public markets this past week, led by high-flying Jamf Holding (JAMF) and the largest SPAC ever Pershing Square Tontine Holdings (PSTHU). Four sizable biotechs all priced at the high end of...read more
Degenerative disease biotech Annexon prices further upsized IPO at $17, above the range
Annexon, a Phase 1 biotech developing therapies for rare autoimmune diseases, raised $251 million by offering 14.8 million shares at $17, above the narrowed range of $15 to $16. The company offered 2.3 million more shares than anticipated. It originally...read more
Degenerative disease biotech Annexon increases proposed deal size by 29% ahead of $194 million IPO
Annexon, a Phase 1 biotech developing therapies for rare autoimmune diseases, raised the proposed deal size for its upcoming IPO on Thursday. The South San Francisco, CA-based company now plans to raise $194 million by offering 12.5 million shares at a...read more